Motivational Interviewing works, but no better than other treatments

Cochrane conducts a meta-analysis of motivational interviewing (MI) and concludes that it's no more effective than other treatments. More than 76 million people worldwide have alcohol problems, and another 15 million have drug problems. Motivational interviewing (MI) is a psychological treatment that aims to help people cut down or stop using drugs and alcohol. The … Continue reading Motivational Interviewing works, but no better than other treatments

Changes in brain gray matter in abstinent heroin addicts

A few years ago, Bill White called for research on the neurobiology of recovery. (He noted that all of our research efforts have been focused on understanding addiction without any research on understanding recovery.) Well, some Chinese researchers have made a contribution. Good news for heroin addicts. Background Previous neuroimaging studies have documented changes in … Continue reading Changes in brain gray matter in abstinent heroin addicts

Response to Why Addiction is NOT a Brain Disease

In a thoughtful post, Marc Lewis questions the disease model of addiction. He doesn't dismiss it out of hand. He seems to look for ways in which it's right and useful. It’s accurate in some ways. It accounts for the neurobiology of addiction better than the “choice” model and other contenders. It explains the helplessness … Continue reading Response to Why Addiction is NOT a Brain Disease

Cognitive performance of opioid maintenance vs. abstinence

  A new study finds lower cognitive functioning in maintenance patients compared with abstinent former users. It also found no difference between methadone patients and buprenorphine patients.   Background To compare the cognitive performances of maintenance patients (MAIN), abstinent ex-users (ABST) and healthy non-heroin using controls (CON). Methods Case control study of 125 MAIN (94 … Continue reading Cognitive performance of opioid maintenance vs. abstinence

Suboxone Strategy: Protecting Patients Or Profits?

I'm a little late on posting this one, but it still seems worth sharing. Reckitt Benckiser has decided to pull Suboxone tablets from the market. Why? It's an evidence-based decision and an expression of their desire to be a good corporate citizen and their concern for children. Late last month, Reckitt Benckiser created a stir … Continue reading Suboxone Strategy: Protecting Patients Or Profits?

Acomprosate – A Randomized, Double-Blind, Placebo-Controlled Study

Recently published and found no "evidence of efficacy for acamprosate compared to placebo". However, "A goal of abstinence was significantly associated with improved drinking outcomes". Efficacy of Acamprosate for Alcohol Dependence in a Family Medicine Setting in the United States: A Randomized, Double-Blind, Placebo-Controlled Study Background Acamprosate has been found to enhance rates of complete … Continue reading Acomprosate – A Randomized, Double-Blind, Placebo-Controlled Study